Display options
Cite
Zhao L, Wang W, Zhong J, et al. The effects of magnesium sulfate therapy after severe diffuse axonal injury. Ther Clin Risk Manag. 2016;12:1481-1486doi: 10.2147/TCRM.S109482.
Zhao, L., Wang, W., Zhong, J., Li, Y., Cheng, Y., Su, Z., Zheng, W., & Guan, X. D. (2016). The effects of magnesium sulfate therapy after severe diffuse axonal injury. Therapeutics and clinical risk management, 121481-1486. https://doi.org/10.2147/TCRM.S109482
Zhao, Ling, et al. "The effects of magnesium sulfate therapy after severe diffuse axonal injury." Therapeutics and clinical risk management vol. 12 (2016): 1481-1486. doi: https://doi.org/10.2147/TCRM.S109482
Zhao L, Wang W, Zhong J, Li Y, Cheng Y, Su Z, Zheng W, Guan XD. The effects of magnesium sulfate therapy after severe diffuse axonal injury. Ther Clin Risk Manag. 2016 Sep 27;12:1481-1486. doi: 10.2147/TCRM.S109482. eCollection 2016. PMID: 27729796; PMCID: PMC5045904.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2016 Sep 27;12:1481-1486. doi: 10.2147/TCRM.S109482. eCollection 2016.

The effects of magnesium sulfate therapy after severe diffuse axonal injury.

Therapeutics and clinical risk management

Ling Zhao, Wei Wang, Jiwen Zhong, YaYun Li, YanZi Cheng, Zhenjiao Su, Wei Zheng, Xiang-Dong Guan

Affiliations

  1. Department of Critical Care Medicine, Zhuhai People's Hospital, Zhuhai, Guangdong.
  2. Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.

PMID: 27729796 PMCID: PMC5045904 DOI: 10.2147/TCRM.S109482

Abstract

PURPOSE: To evaluate the clinical effects of magnesium sulfate in the treatment of diffuse axonal injury (DAI).

PATIENTS AND METHODS: This study was a randomized, double-blind, placebo-controlled trial conducted in the First Affiliated Hospital of Sun Yat-sen University, Guangzhou and Zhuhai People's Hospital, Zhuhai, two trauma center hospitals. A total of 128 patients suffered from DAI, with initial Glasgow coma scale (GCS) scores of 3-8. They were randomly divided into two groups: magnesium sulfate treatment (MST) group (n=64) and control group (n=64). The MST group received 250 μmol/kg magnesium sulfate intravenously 20 minutes after admission, followed by 750 μmol/kg magnesium sulfate intravenously daily for 5 days. The control group received standard management without MST. GCS scores and serum neuron-specific enolase values were measured and recorded at admission, and on days 3 and 7 after injury. Outcomes were determined by Glasgow outcome scale scores at discharge and at 3 months' follow-up, respectively.

RESULTS: After the 7-day treatment, patients in the MST group, compared with those in the control group, had a lower serum neuron-specific enolase level (25.40±6.66 vs 29.58±7.32, respectively,

CONCLUSION: Early treatment with magnesium sulfate resulted in a significant improvement in DAI outcome. Further studies are needed to confirm the clinical significance of treatment of DAI patients with magnesium sulfate.

Keywords: diffuse axonal injury; magnesium sulfate; outcome

References

  1. J Neurotrauma. 1994 Aug;11(4):357-68 - PubMed
  2. Restor Neurol Neurosci. 2005;23(2):67-77 - PubMed
  3. Neurosci Lett. 1990 Jul 31;115(2-3):293-9 - PubMed
  4. J Neurosurg. 1999 Mar;90(3):504-9 - PubMed
  5. J Neurosurg. 1996 Jul;85(1):117-24 - PubMed
  6. Clin Interv Aging. 2014;9:17-21 - PubMed
  7. PLoS One. 2013 Nov 13;8(11):e79982 - PubMed
  8. J Neurotrauma. 2014 Sep 1;31(17):1486-96 - PubMed
  9. Biochim Biophys Acta. 1993 Oct 20;1182(3):329-32 - PubMed
  10. Stroke. 1998 May;29(5):918-23 - PubMed
  11. J Neurotrauma. 2015 Mar 1;32(5):359-65 - PubMed
  12. J Neurosurg. 1996 Jul;85(1):131-7 - PubMed
  13. Neurosci Lett. 1990 Feb 5;109(1-2):234-8 - PubMed
  14. J Neurotrauma. 1994 Apr;11(2):173-86 - PubMed
  15. J Neurotrauma. 1996 Mar;13(3):139-47 - PubMed
  16. Clin Interv Aging. 2012;7:51-4 - PubMed
  17. Brain Res. 1996 Oct 28;738(1):150-3 - PubMed
  18. Neurosci Res. 2014 Jul;84:72-8 - PubMed
  19. Magnes Res. 2007 Dec;20(4):229-36 - PubMed
  20. Brain. 2012 Apr;135(Pt 4):1268-80 - PubMed
  21. Histopathology. 1989 Jul;15(1):49-59 - PubMed
  22. J Neurotrauma. 2014 Jan 15;31(2):206-14 - PubMed
  23. Pediatr Res. 1999 Sep;46(3):281-6 - PubMed
  24. Neurosci Lett. 2003 Jan 9;336(1):41-4 - PubMed
  25. Brain Pathol. 1992 Jan;2(1):1-12 - PubMed

Publication Types